Bristol-Myers Squibb Company Completes Acquisition of KOSAN Biosciences, Inc.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has completed its previously announced $190 million acquisition of Kosan Biosciences Incorporated (NASDAQ: KOSN) (“Kosan”). As a result of the transaction, Kosan has become a wholly-owned subsidiary of Bristol-Myers Squibb.